Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Angus

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Journal of Gastroenterology and Hepatology|November 7, 2019
Increasing prevalence of primary biliary cholangitis in Victoria, AustraliaJanine French, Ingrid van der Mei, Steve Simpson, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|November 10, 2015
Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinomaKonstantin Kazankov, Anthony Rode, Kira Simonsen, et al.
European Journal of Gastroenterology & Hepatology|May 4, 2016
Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b studyStefan Zeuzem, Parvez Mantry, Vicente Soriano, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|January 5, 2019
Increasing Incidence of Nonalcoholic Steatohepatitis as an Indication for Liver Transplantation in Australia and New ZealandLuis Calzadilla-Bertot, Gary P Jeffrey, Bryon Jacques, et al.
Journal of Gastroenterology and Hepatology|August 28, 2015
Circulating CD147 predicts mortality in advanced hepatocellular carcinomaAimei Lee, Anthony Rode, Amanda Nicoll, et al.
Antimicrobial Agents and Chemotherapy|September 27, 2017
Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease InhibitorLuzelena Caro, Larissa Wenning, Zifang Guo, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 13, 2012
Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interactionToshihiko Nishimura, Toshiko Nishimura, Yajing Hu, et al.
Hepatology (Baltimore, Md.)|June 24, 2008
Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistanceScott Preiss, Margaret Littlejohn, Peter Angus, et al.
Scientific Reports|September 27, 2017
Increased liver AGEs induce hepatic injury mediated through an OST48 pathwayAowen Zhuang, Felicia Yt Yap, Clinton Bruce, et al.
Gastroenterology|September 20, 2011
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infectionStefan Zeuzem, Tarik Asselah, Peter Angus, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Journal of Gastroenterology and Hepatology|November 7, 2019
Increasing prevalence of primary biliary cholangitis in Victoria, AustraliaJanine French, Ingrid van der Mei, Steve Simpson, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|November 10, 2015
Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinomaKonstantin Kazankov, Anthony Rode, Kira Simonsen, et al.
European Journal of Gastroenterology & Hepatology|May 4, 2016
Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b studyStefan Zeuzem, Parvez Mantry, Vicente Soriano, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|January 5, 2019
Increasing Incidence of Nonalcoholic Steatohepatitis as an Indication for Liver Transplantation in Australia and New ZealandLuis Calzadilla-Bertot, Gary P Jeffrey, Bryon Jacques, et al.
Journal of Gastroenterology and Hepatology|August 28, 2015
Circulating CD147 predicts mortality in advanced hepatocellular carcinomaAimei Lee, Anthony Rode, Amanda Nicoll, et al.
Antimicrobial Agents and Chemotherapy|September 27, 2017
Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease InhibitorLuzelena Caro, Larissa Wenning, Zifang Guo, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 13, 2012
Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interactionToshihiko Nishimura, Toshiko Nishimura, Yajing Hu, et al.
Hepatology (Baltimore, Md.)|June 24, 2008
Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistanceScott Preiss, Margaret Littlejohn, Peter Angus, et al.
Scientific Reports|September 27, 2017
Increased liver AGEs induce hepatic injury mediated through an OST48 pathwayAowen Zhuang, Felicia Yt Yap, Clinton Bruce, et al.
Gastroenterology|September 20, 2011
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infectionStefan Zeuzem, Tarik Asselah, Peter Angus, et al.
Pageof 6